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Portal hypertensionIn our previous study, miR-126 was identiﬁed as one of the leading miRNAs that is downregulated
during activation of hepatic stellate cells (HSCs). However, the roles and related mechanisms of
miR-126 in HSCs are not understood. In this study, we compared expression of miR-126 during
HSC activation both in vitro and in vivo. We also applied RNA interference to analyze the role and
mechanism of miR-126⁄ in the activation of HSCs. Restoring HSCs with Lv-miR-126⁄ resulted in
decreased proliferation, accumulation of extracellular matrix components, and cell contraction,
while also negatively regulating the vascular endothelial growth factor (VEGF) signal transduction
pathways by partially targeted VEGF-A. Thus, we postulate that miR-126 may be a biological marker
for the activation of HSCs, and useful for reducing intrahepatic vascular resistance and improving
the sinusoidal microcirculation in chronic liver diseases.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Accumulating evidence suggests that hepatic stellate cells
(HSCs) are key players in the pathogenesis of the increased intrahe-
patic vascular resistance in chronic liver diseases, in which HSCs
proliferate, acquire characteristics of contractile cells, and undergo
trans-differentiation leading to a myoﬁbroblast phenotype [1,2]. A
majority of growth factors and related pathways are involved in
the dynamic biological behavior change of HSCs. Among them, vas-
cular endothelial growth factor (VEGF)-A is probably the most
important [3]. However, full understanding of HSCs activation is
still beyond our reach because of its complexity, especially the
intricate regulation of gene expression.
miRNAs are several small non-coding RNAs of 21–25 nt that
usually negatively modulate gene expression at the post-transcrip-
tional level by incomplete or complete complementary binding to
target sequences within the 30untranslated region (UTR) of miRNA
[4]. Previously, we reported the biological functions and targets ofsome miRNAs and revealed the signaling pathways regulated by
these miRNAs in the activation of HSCs [5,6]. For instance,
miR-15 and miR-16 regulate HSC cell growth, apoptosis and prolif-
eration by targeting proteins involved in apoptosis and grow
pathways [5,7]. These ﬁndings suggest that altered expression of
miRNAs may be associated with ﬁbrogenesis, but more studies
are required to clarify the mechanism of miRNAs in the develop-
ment and progression of liver diseases.
In our previous miRNA expression proﬁling study, miR-126 was
downregulated during the activation of HSCs, and appeared to be
the most enriched in quiescent stellate cells. Meanwhile, bioinfor-
matics analysis revealed that the VEGF signaling pathway is the
most enriched of these differentially upregulated signaling
pathways in HSC activation. According to gene ontology (GO) and
Kyoto Encyclopedia of Genes and Genomes (KEGG) orthology
(KO) analyses, we found that miR-126⁄ is most likely related to
the biological behavior of HSCs by partially targeting VEGF-related
signaling pathways [5,6]. Here, we demonstrated the dynamic
expression of miR-126⁄ in chronic liver diseases, and performed
an overall analysis of its effects and its related mechanisms on bio-
logical properties of HSCs, on the basis of miRNA expression proﬁle
and bioinformatics interpretation. These ﬁndings may not only
increase our current knowledge about the signiﬁcance of HSC bio-
logical behavior, but also provide a novel therapeutic strategy
against intrahepatic vascular resistance in chronic liver diseases.
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2.1. Isolation, culture, and identiﬁcation of rat HSCs
Primary HSCs were isolated from three normal male Sprague–
Dawley rats (400–500 g) by in situ perfusion and density-gradient
centrifugation [8]. The rats received humane care according to the
Guide for the Care and Use of Laboratory Animals of Shanghai Jiao-
tong University School of Medicine. All the materials for HSC isola-
tion were obtained from commercial sources as previously
described [5].
The isolated HSCs were cultured in Dulbecco’s Modiﬁed Eagle’s
Medium, supplemented with 10% fetal bovine serum, 100 U/ml
penicillin, 100 mg/ml streptomycin, and 2 mmol/l glutamine. Qui-
escent and totally activated HSCs were harvested on days 2 and 14.
Their purity was detected by immunocytochemistry for desmin
(Sigma, St Louis, MO, USA) (1:100). Cell viability was determined
by trypan blue staining.
2.2. Animal model of liver ﬁbrosis and histological examination
Thirty-six Sprague–Dawley rats (250–400 g, Laboratory
Animals of Shanghai Jiaotong University School of Medicine) were
divided into 3 groups of 12 (normal, control, and ﬁbrosis model).
Fibrosis model rats were injected subcutaneously with 40% CCl4
(3 ml/kg, CCl4:olive oil, 2:3) every 3 days for 8 weeks. Control rats
received only olive oil in the same way. Rats were sacriﬁced at
8 weeks and the degree of liver ﬁbrosis was determined by micros-
copy. The intra-hepatic HSCs were isolated from CCl4-induced
ﬁbrotic rat livers.
Liver tissues were ﬁxed with 4% formaldehyde in phosphate-
buffered saline (PBS) and embedded in parafﬁn, and 5-lm-thick
section were prepared. All the sections were stained with hema-
toxylin and eosin and standard Van Gieson (VG) staining, which
was used to detect collagen ﬁbers. Total RNA from rat HSCs was
prepared as described previously [6]. Fibrosis was graded accord-
ing to the Ishak modiﬁed staging system [9]. Histopathology was
interpreted by two independent board-certiﬁed pathologists who
were blind to the study.
2.3. Immunoﬂuorescence staining of HSCs
The expression of VEGFA in quiescent (2 days) and in culture-
activated HSCs (14 days) was evaluated by immunocytochemistry.
The adherent HSCs were ﬁxed with 4% paraformaldehyde and
permeabilized with 0.1% Triton X-100 (Sigma, St Louis, MO, USA).
Following blocking in 10% preimmune goat serum for 2 h, cells
were incubated with mouse monoclonal anti-VEGFA (1:100, Santa
Cruz, USA) overnight at 4 C. Then cells were incubated with
TRITIC-conjugated donkey anti-mouse IgG (Sigma; 1:100) for 1 h.
TRITIC ﬂuorescence were visualized using a ﬂuorescence micro-
scope. The positive cells of three randomly selected areas per slide
from three slides was used to calculate the expression of VEGFA in
HSCs.
2.4. Double immunostaining on cryosections of rat liver
Double immunostaining on cryosections of rat liver were per-
formed as described [10,11]. Liver tissue from ﬁve rats per group
were blocked with 0.3% H2O2 in methanol for endogenous peroxi-
dase activity. double staining experiments on rat livers for desmin
in combination with VEGFA were performed. Immunohistochemi-
cal examination was carried out by a researcher blind to the exper-
imental design. The percentage of cells co-expressing VEGF/desmin
was determined by counting the number of VEGF-positive cells indesmin-positive cells in three different ﬁelds per slide from three
slides.
2.5. Lentiviral construction, production and transfection
The precursor miR-126⁄ (pre-miR-126) sequences were ob-
tained from miRBase (http://microrna.sanger.ac.uk/sequences/).
The premiR-126 sense and antisense primers were: 50-GCGAATTC-
CAGAGGGCAGCTAGCCCT-30, 50- GCGGATCCAAGCCTCACCTGTTCT-
30. Lentivector Expression System was purchased from System
Biosciences. Packaging and production of lentivirus were per-
formed according to the manufacturer’s protocol. Brieﬂy, we ﬁrst
extracted DNA, then designed PCR primers. The product was
ampliﬁed by PCR contains a sequence of miRNA precursor, which
was conﬁrmed by enzyme digestion and then cloned into into
the pCDH-CMV-MCS-EF1-copGFP miRNA expression vector (Sys-
tem Biosciences). The new miRNA expression vectors (pCDH-
CMV-MCS-EF1-copGFP-miR-126) and Lentivirus Package plasmid
mix (System Biosciences) were cotransfected into 293TN cells with
Lipofectamine 2000 (Invitrogen). The culture supernatants were
collected, concentrated, and used as a virus stock. The viral titer
was determined by counting green ﬂuorescent protein (GFP)-posi-
tive cells after transfection.
Primary myoﬁbroblast-like HSCs, which had experienced total
activation at day 14 and then divided into a blank group, Lv-GFP
group, and Lv-miR-126⁄ group with a multiplicity of infection
(MOI) from 10 to 50. For 24 h prior to infection, HSCs were plated
in each well of 6-well plates, then infected with recombinant
viruses (Lv-miR-126⁄ or LV-GFP) at different MOI of for 6 h at
37 C, followed by the addition of fresh growth medium. Three
days later, all lentiviral vectors expressed enhanced GFP, which al-
lowed for titration and measurement of their infection efﬁciency in
transfected cells.
2.6. Quantitative reverse transcriptase polymerase chain reaction (RT-
PCR) analysis of miR-126⁄ and VEGF expression
HSCs from 3 rats per group were isolated from rat livers by per-
fusion of collagenase and pronase, followed by centrifugation over
Nycodenz gradient, as described above. RNA purity and concentra-
tion were determined by electrophoresis and a BioPhotometer
(Eppendorf AG, Hamburg, Germany). The extracted total RNA of
HSCs from the three groups was reverse transcribed into cDNA
using ExScriptTM RT reagent Kit (TAKARA, Kusatsu, Japan). Expres-
sion of mature miRNA was assayed using stem-loop RT followed by
PCR analysis, as previously described [5]. PCR analysis was per-
formed in triplicate for each sample. The relative amount of miRNA
was normalized against U6 snRNA and VEGF was normalized
against GAPDH, and the fold change was calculated by the 2DDCt
method. Primer sequences were listed in Table 1.
2.7. Detection of VEGF-A pathway by Western blotting
Total proteins were prepared by standard procedures and
quantiﬁed by the BCA method (Pierce, Rockford, IL, USA). Thirty
micrograms of protein per sample were loaded onto a 10%
SDS–polyacrylamide gel. After electrophoresis, the protein was
transferred onto a polyvinylidene diﬂuoride membrane (Millipore,
Billerica, MA, USA) by electro-elution. The membrane was incu-
bated with anti-VEGF-A (1:500; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) / phosphoinositide 3-kinase (PI3K; 1:200; Santa
Cruz Biotechnology)/AKT (1:200; Santa Cruz Biotechnology)/
CCND1 (1:100; Santa Cruz Biotechnology) antibody overnight at
4 C and with horseradish-peroxidase-conjugated goat anti-mouse
IgG (1:2000; Jackson ImmunoResearch, West Grove, PA, USA) for
2 h at room temperature. After washing, the membrane was
Table 1
Primers used in qRT-PCR.
Gene Sense primers Antisense primers
miRNA126⁄ 50-CATTATTACTTTTGGTACGCG-30 50-GTCGTATCCAGTGCGTGTCGTG-30
U6 50-GCTTCGGCAGCACATATACTAAAAT-30 50-CGCTTCACGAATTTGCGTGTCAT-30
VEGF-A 50-TGCAGATCATGCGGATCAAAC-30 50-TTTCTCCGCTCTGAACAAGGC-30
GAPDH 50-ACCACAGTCCATGCCATCAC-3’ 50-TCCACCACCCTGTTGCTGTA-30
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strate (Pierce) and anti-actin antibody (Santa Cruz Biotechnology)
(1:500) as an internal standard.
2.8. Luciferase activity assay
The 30UTR of rat VEGF-A cDNA containing the putative target site
for miR-126⁄ was ampliﬁed by PCR and inserted into the pGL3 con-
trol vector (Promega, Madison, WI, USA) immediately downstream
from the stop codon of luciferase (pGL3-VEGFA-30UTR). A mutant
version of the 30UTR, with a deletion of 7 bp from the site of perfect
complementarity was also generated by the QuikChange II Site-Di-
rected Mutagenesis Kit (Stratagene, La Jolla, CA, USA). For reporter
assays, cells were transiently transfected with wild-type or mutant
reporter plasmid, ﬁreﬂy and Renilla luciferase activities were
measured consecutively by dual-luciferase assays kit (Promega)
24 h after transfection.
2.9. In vitro proliferation and cell cycle assay
Cells were seeded in 96-well plates and cultured for 24 h. Cells
were starved for 24 h by replacing the medium with serum-free
medium, followed by infection with recombinant viruses (Lv-
miR-126⁄ or Lv-GFP) at MOI 50. Cell culture was continued forFig. 1. HE and Van Gieson staining of liver tissue (100). HE staining of normal and CCl4
normal and CCl4-treated liver tissue is shown in panels (C), (D), respectively.24, 48 and 72 h and assessed using the Cell Counting Kit 8
(Dojindo, Kumamoto, Japan). The absorbance value of each well
was determined at 450 nm using a microplate reader (Molecular
Devices, Tokyo, Japan).
Cells were transfected with Lv-miR-126⁄. At 72 h after transfec-
tion, ﬂoating and adherent cells were harvested, combined, and
processed. Alternatively, nocodazole (100 ng/ml; Sigma–Aldrich,
St Louis, MO, USA) was added and cells were further incubated
for 16–20 h before harvesting. The supernatant from each well
was combined with cells harvested from each well by trypsiniza-
tion. Cells were collected by centrifugation, ﬁxed with ice-cold
70% ethanol, washed with PBS, and resuspended in 0.5 ml PBS con-
taining propidium iodide (0.5 mg/ml in PBS with 0.1% sodium
azide, pH approximately 7.4) and RNase A (1 mg/ml). After ﬁnal
incubation at 37 C for 30 min, cells were analyzed using a FAC-
SCalibur ﬂow cytometer (Becton–Dickinson, CA, USA). Data were
analyzed using FlowJo software (Tree Star, Ashland, OR, USA).
2.10. Measurement of cytosolic free Ca2+ and cell contraction
After incubating in 1 ml Fluo-3/AM (5 lmol/l) at 37 C for
40 min, the HSCs were washed 3 times with PBS, resuspended,
and ﬁltered through a 200-screen mesh, and cells were collected
and detected with ﬂow cytometry [12]. Contractility of hydrated-treated liver tissue is shown in panels (A), (B), respectively. Van Gieson staining of
Fig. 2. Immunoﬂuorescence staining of quiescent and activated HSCs for VEGFA (200). Hoechst 33258 nuclear staining for all conditions is shown in panels.
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according to the method of Rockey and Weisiger [13].
2.11. Enzyme-linked immunosorbent assay (ELISA)
Cells were seeded in 6-well plates and cultured for 24 h. Cells
were starved for 24 h by replacing the medium with serum-free
medium, and treated with Lv-miR-126⁄ (MOI: 1:50). Cell culture
supernatants were collected after 72 h. Hyaluronic acid (HA),
laminin (LN), procollagen type III (PC III), and type IV collagen
(COL IV) were measured using ELISA kits (R&D Systems Inc, Minne-
apolis, MN, USA) according to the procedure recommended by the
manufacturer.
2.12. Statistical analysis
All the results are expressed as mean ± standard deviation
(S.D.). Statistical analysis was performed using the Student’s t test
for comparison of two groups, and analysis of variance for multiple
comparisons. In both cases, differences of P < 0.05 were considered
statistically signiﬁcant.
3. Results
3.1. In vitro activation of rat HSCs
About 5  108 ml1 HSCs were harvested from each rat. The
percentage of freshly isolated living HSCs was up to 95% as deﬁnedby trypan blue staining. More than 95% of the HSCs showed posi-
tive desmin staining on days 2 and 14, indicating high purity of
HSCs as previously described [5].
3.2. CCl4 induced liver ﬁbrosis in rats
Histological examination, classiﬁed according to the grade of
liver ﬁbrosis, revealed that the degree of liver ﬁbrosis progressed
in rats that received CCl4 relative to rats receiving olive oil alone.
Fig. 1 revealed little ﬁbrosis in the liver of normal rats. On the con-
trary, hepatic steatosis, necrosis and inﬁltration of inﬂammatory
cells were obvious in the ﬁbrosis model group. Moreover, there
was nodular ﬁbrosis with extensive collagen deposition and well-
delineated ﬁbrosis septa, which were continuous and extended in
each section, sometimes even bridging portal regions. In contrast
to the normal rats (stage 0), the Ishak staging for the ﬁbrosis model
group (10 w) reached 5.4 ± 1.0.
3.3. Differential expression of miR-126⁄ and VEGF-A during HSC
activation both in vivo and vitro
Intrahepatic HSCs were isolated from rat liver with CCl4-in-
duced experimental ﬁbrosis, and then subjected to both Quantita-
tive RT-PCR and dual-immunoﬂuorescent staining. Being evaluated
by these two assays both in vivo and vitro (Figs. 2–4), the VEGF
expression was virtually undetectable in quiescent HSCs. However,
dramatic increase of VEGF level occurred in HSCs after their activa-
tion both in vivo and vitro (P < 0.05). This result was vice versa for
Fig. 3. Double immunoﬂuorescence staining of VEGFA and desmin in liver tissue.(200): double staining of desmin (red), VEGF (green) and Hoechst in nuclei (blue) was in
the liver tissue. At the arrowheads were the expression of VEGFA in HSCs showing red-green double stained cytoplasm and blue-stained nuclei.
Fig. 4. mRNA relative levels of miR-126⁄ and VEGF-A by quantitative real-time PCR.
(A) Relative expression of miR-126⁄ and VEGF-A on days 2 and 14 in vitro. (B)
Relative expression of miR-126⁄ and VEGF-A in the intrahepatic HSCs after CCl4
injury. Statistically signiﬁcant differences between groups is indicated by P < 0.05.
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tion (P < 0.05).
3.4. Lentiviral delivery of miR-126⁄
The recombinant plasmid pCDH-CMV-MCS-EF1-copGFP-miR-
126 was conﬁrmed by restriction endonuclease analysis and DNA
sequencing. Virus titer was 108 > ifu/ml. the efﬁciency of transfec-
tion was estimated by determining the percentage of GFP-positive
cells and ﬂuorescence-activated cell sorting conﬁrmed that 99% of
HSCs were transduced with Lv-miR-126⁄ (MOI:50). The following
assays were done with Lv-mediated gene transfer at MOI 50.
3.5. Effect of miR-126⁄ on inhibition of VEGF expression and
inactivation of PI3K/AKT pathway
Examination of the homology between rno-mir-126⁄ and VEGF-
A mRNA sequences showed that the 7 nucleotides in the seed re-
gion of miR-126⁄ were complementary to bases 3380–3386 of
VEGF-A 30UTR (NM_031836.2). Thus an inhibitory effect of miR-
126⁄ on VEGF-A was inferred.
HSCs treated with Lv-miR-126⁄ at MOI 50 for 72 h, and the
expression of miR-126⁄ increased signiﬁcantly. To investigate fur-
ther the actions of miR-126⁄ on VEGF-A, we investigated the
expression of VEGF-A at the mRNA and protein levels. mRNA level
Fig. 5. (A) VEGF-A is the target of miR-126⁄. miR-126⁄ shares the conserved binding sites in VEGF-A 30UTR. The site of target mutagenesis is indicated. (B) mRNA levels of miR-
126⁄ in HSCs analyzed by quantitative real-time PCR. (C) Protein levels of the VEGF-A/PI3K/AKT/CCND1 pathway detected by Western blotting. Data are expressed as
means ± S.D. of 3 observations. ⁄P < 0.05, ⁄⁄P < 0.01 versus corresponding control using Student’s t test.
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niﬁcantly compared with those in the controls (P < 0.05). Western
blotting also showed that restored Lv-miR-126⁄ reduced its down-
stream protein expression, including PI3K, phospho-AKT (p-AKT)
and CCND1 (cyclin D1), which is considered to play an important
role in the biological behavior of HSCs (Fig. 5).
To assess further whether miR-126⁄ directly regulated VEGF-A
expression through the target site at the 30-UTR of VEGF-A mRNA,
we used a luciferase reporter assay. A signiﬁcant decrease in rela-
tive luciferase activity was noted when pGL3-VEGFA 30UTR was
cotransfected with miR-126⁄. In contrast, the inhibitory effectwas abolished by partial deletion of the perfectly complementary
sequences in the VEGF-A 30-UTR (pGL3-mutVEGFA-30-UTR), which
disrupted the interaction between miR-126⁄ and VEGF-A (Fig. 6).
3.6. Effects of upregulated expression of miR-126⁄ on proliferation and
contraction of HSCs
To verify whether the miR-126⁄ family affected biological
behavior of HSCs by regulating the VEGF pathway, we measured
cell proliferation using the cell proliferation assay. Fig. 7A shows
that inhibition of VEGF-A expression by RNA interference
Fig. 6. Dual luciferase assay performed in activated HSCs transfected with
luciferase construct alone or cotransfected with Lv-miR-126⁄ or Lv-GFP. Fireﬂy
luciferase construct containing mutant (MutpGL3-VEGFA) target site of the VEGF-A
30UTR was generated and transfected as indicated. Fireﬂy luciferase activity was
normalized to Renilla luciferase activity for each sample. The results are expressed
as the mean ± S.D. from 3 independent experiments. ⁄P < 0.01 compared to
corresponding control.
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HSCs transfected with miR-126⁄ had increased numbers of cells
in G0/G1 phase, corresponding decreases in S phase, but no
signiﬁcant difference in G2/M phase. These results indicate that
miR-126⁄ contributed to induction of G0/G1 arrest in HSCs, which
was partially through downregulation of the PI3K/AKT/CCND1
pathway (Fig. 7B and C).
The cytosolic free Ca2+ and cell contraction were also measured.
Intracellular calcium concentration in HSCs was determined by
ﬂow cytometry using calcium ﬂuorescent probe Fluo-3/AM. The
mean ﬂuorescence intensity (MFI) of Fluo-3/AM in Lv-miR-126⁄Fig. 7. Inactivation of VEGF-A/PI3k/Akt/CCND1 pathway by miR-126⁄ suppressed prolif
proliferation was analyzed using CCK-8 cell proliferation assay kits. Each value represent
was suppressed signiﬁcantly compared with cells that were not transfected or were traHSCs was 33.20 ± 5.60 and 204.92 ± 20.87 in the control group,
which demonstrated that the intracellular calcium concentration
in HSCs in the Lv-miR-126⁄ group was signiﬁcantly decreased
(P < 0.01) (Fig. 8).
As shown in Fig. 9, when activated HSCs were cultured on
collagen gels for 9 days, the diameter of the gels signiﬁcantly de-
creased to 34.7 ± 6.5% (mean ± S.D. of 3 wells; P < 0.05 vs DMEM
alone), The surface of the collagen gels on which stellate cells or
Lv-control were plated became obviously concave. On the other
hand, Lv-miR-126⁄ addition to the medium signiﬁcantly inhibited
the contraction of collagen gels (17.0 ± 5.2% of the original
diameter).
3.7. Effect of miR-126⁄ targeting of VEGF-A on ECM degradation
modulators
After treatment with miR-126⁄ for 72 h, the contents of HA, LN,
PC III and COL IV in the cell culture supernatant were signiﬁcantly
inhibited compared with the normal and control groups (P < 0.01)
(Table 2).
4. Discussion
The miR-126 family is known to be associated with angiogene-
sis, and has been extensively analyzed in tumor cell lines [14,15].
miR-126/miR-126⁄ is located within the egﬂ7 (epidermal growth
factor-like domain 7, EGFL7) gene, which is implicated in vessel
development through promoting VEGF signaling, angiogenesis,
and vascular integrity. It is also involved in cell-growth regulation
in several diseases, such as colorectal cancer, gastric cancer, and li-
ver carcinoma, by regulating multiple target genes including IRSeration and induced G0/G1 arrest in HSCs. (A) The proliferation curve of HSCs. Cell
s the mean of six replicates. The proliferation of HSCs transfected with LV-miR-126⁄
nsfected with control vector. (B and C) HSCs cell cycle was analyzed by FACS.
Fig. 8. Intracellular calcium concentrations in HSCs detected by ﬂow cytometry: untransfected group (215.03); control group (204.92); LV-miR-126⁄ group (33.24). Restoring
the intracellular miRNAs by miR-126⁄ administration greatly decreased the intracellular calcium concentration in HSCs. ⁄⁄P < 0.01 versus corresponding control using
Student’s t test.
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have all been shown to be biological targets of miR-126 [14–20].
Among these target genes, VEGFA, PI3K, AKT and CCND1 within
the our previous miRNA-gene networks, which had the highest
ratio and enrichment in the VEGF-related pathway, were noted
[6]. VEGF-A, which is detected at a low level in quiescent HSCs, is
overexpressed in culture-activated HSCs and intrahepatic HSCs
after liver injury [20,21]. Recent studies showed early proliferative
responses in HSC activation, and the contractile nature of the HSCswas mainly mediated by VEGF pathways [22]. In end-stage liver
disease, VEGF-mediated HSC activation is considered to be the ma-
jor ECM producer responsible for ﬁbrogenesis, and is a mechanistic
factor in intrahepatic vascular resistance and pressure regulation
[22,23]. Furthermore, administration of VEGF blockers signiﬁcantly
decreases intrahepatic vascular resistance in portal hypertensive
syndrome [24]. Using bioinformatics tools, we found that miR-
126⁄ was the only miRNA targeting VEGF-A with 7 complementary
nucleotides. Moreover, the level of miR-126⁄ was inversely
Fig. 9. Contraction of hydrated collagen gels induced by cultured stellate cells. Lv-miR-126⁄ addition to the medium signiﬁcantly inhibited the contraction of collagen gels.
⁄P < 0.05 versus corresponding control using Student’s t test.
Table 2
Effect of miR-126⁄ targeting VEGFA on HA, LN, PC III and COL IV.
HA (ng/ml) LN (ng/ml) PC III (ng/ml) COL IV (ng/ml)
Blank (70.3 ± 3.6)% (54.5 ± 3.4)% (42.1 ± 3.1)% (32.4 ± 2.3)%
Lv-GFP (75.3 ± 3.0)% (53.3 ± 2.7)% (46.2 ± 2.3)% (34.2 ± 4.3)%
Lv-miR-126⁄ (20.9 ± 4.8)%# (21.8 ± 5.4)%# (11.9 ± 3.3)%# (12.1 ± 4.2)%#
# Indicates P values < 0.01 between blank and Lv-miR-126⁄.
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in vitro and in vivo, which was also in agreement with earlier stud-
ies in other tumor lines [25]. miR-126⁄ likely plays important roles
in the proliferation and contraction of HSCs by targeting VEGF-A.
Our ﬁndings were consistent with these predictions. The VEGF-
A/PI3K/AKT pathway had a critical role in the activation of HSCs,
and VEGF-A was detected at the protein and mRNA levels in acti-
vated rather than quiescent HSCs. Moreover, restored miR-126⁄
greatly reduced VEGF-A, but not VEGF-A mRNA, and the luciferase
activity of VEGF-A 30UTR-based reporter construct in HSCs. Thus,
VEGF-A was indicated to be a direct target of miR-126⁄. As a result,
downstream target genes such as VEGF-A (PI3K, p-AKT, CCND1)
were inactivated, followed by decreased cytosolic free Ca2+ , which
is considered to be associated with HSC proliferation and contrac-
tion [26,27]. A combination of CCK8 and ﬂow cytometry conﬁrmed
marked cell cycle arrest in miR-126⁄-treated activated HSCs. This
provides the ﬁrst evidence that restoration of the level of miR-
126⁄ induces G0/G1 phase arrest in HSCs with a myoﬁbroblast-like
phenotype, partially by regulating the Vegf/PI3k/Akt/CCND1 path-
way. Besides, during ﬁbrosis progression and portal hypertension,
ECM accumulation and activated HSC contraction are key trigger-
ing factors [22]. Our results suggest that miR-126⁄ interplays with
the Vegf/PI3k/Akt/CCND1 pathway and VEGF-A/Ca2+ pathway,
thereby blocking ECM accumulation and contraction of HSCs,
respectively.Regulation of the biological behavior of HSCs is a complex
process. Increasing evidence indicates that there are other miRNAs,
related target genes and pathways involved in cell biological pro-
cesses other than miR-126⁄ and its induced pathway, such as
miR-181b and miR-150 [28,29], but they were not in our miRNA
gene network-related pathways. However, it is likely that there
may be other miRNAs relevant to the biological changes in HSCs.
In conclusion, our results show that miR-126⁄ may participate
in the regulation of HSC contractility and proliferation in chronic
liver diseases, partially by targeting the VEGF-mediated signaling
pathway. These ﬁndings may not only highlight the essence of
intrahepatic vascular resistance due to liver diseases, but also facil-
itate novel therapeutic strategies against portal hypertension and
offer insight into its progression.
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